ClinicalTrials.gg
CompletedNCT00088153Updated Nov 2, 2021Results posted

Effects of Anorexia Nervosa on Bone Mass in Adolescents

A Phase 2/3 interventional study of Physiologic Estrogen/progesterone and Placebo in Anorexia Nervosa, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to female participants aged 12 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-02.

Sponsored by Massachusetts General Hospital · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Anorexia Nervosa by Massachusetts General Hospital — 2 open to participants now, 2 under way, none of them phase 3. Anorexia Nervosa · Massachusetts General Hospital.

Enrollment
4th of 15
110 · median 40
Started
2003
with 1 other
Phase 2/3
2 of 16
none open now
Registered
1st of 16
by date

Among the 16 studies in Anorexia Nervosa by Massachusetts General Hospital, this one is the 4th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2003, is one of 2 in phase 2/3, and was the 1st registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

2 of the 16 studies in Anorexia Nervosa by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 12 Years to 18 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Anorexia Nervosa by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This study is to determine the effects of anorexia nervosa on bone mass and hormone levels in adolescents. Whether administration of estrogen, a normal hormone present during puberty, can help maintain bone development in girls with anorexia nervosa will be determined.

Read the detailed description

Adolescence is a critical time for bone mineral accretion as between 60-90% of peak bone mass is established during this period, and peak bone mass is a major determinant of bone density and osteoporosis risk during adulthood. Anorexia nervosa (AN) is the third most common chronic illness among adolescent girls, with a prevalence of 0.2-1.0%. Therefore, AN occurs at a time during which patients are the most vulnerable to disruption of bone mineral accretion. Osteopenia is a major co-morbid complication of AN in 50-75% of female adolescents and adult women with this eating disorder. Women with the onset of the disorder during adolescence have more severe osteopenia than women with onset during adulthood. Little is known about the pathogenesis of osteopenia in this adolescent population and there are no established therapies. Improved understanding of bone mineral metabolism and factors which predict recovery of bone mineral accretion are critical in the development of therapeutic strategies to preserve and maximize bone mass in girls with the onset of AN during adolescence. Estrogen is known to be a critical factor in the development of peak bone mass. Although AN is associated with profound estrogen deficiency, there are no controlled studies investigating the effects of estrogen administration in this population.

This research proposal will address critical unanswered questions regarding bone abnormalities in adolescents with anorexia nervosa. Defining changes in bone formation with weight recuperation and hormonal variables would provide insight into the factors essential for bone mineral accretion during adolescence, as well as those that predict recovery. Determination of dose-dependent estrogen effects in this population will be key in targeting interventions during the time of active disease, with the long-term goal of preserving peak bone mass accretion in this vulnerable group of patients. Data obtained from women with post-menopausal osteoporosis or from women with AN cannot be extrapolated to adolescent patients who are in an active period of bone growth and mineralization as well as remodeling. Given the increasing prevalence of AN and its profound consequences on bone health, these studies will provide much needed data to enable treatment strategies for this severe co-morbid disease.

03

Conditions studied

  • Anorexia Nervosa

Keywords

  • Anorexia Nervosa
  • Amenorrhea
  • Bone Mass
  • Growth hormone
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females Only with Anorexia Nervosa and Amenorrhea 12-18 years
  • Normal-weight girls 12-18 years with no past or present history of an eating disorder

Exclusion criteria

Exclusion Criteria:

  • Diseases affecting bone metabolism (including untreated thyroid disease, premature ovarian failure, diabetes, cancer, pituitary, renal disease or bone fracture within the past six months)
  • Use of prescription medications affecting bone metabolism within three months
  • Suicidality
  • Psychosis
  • Substance abuse
  • Hematocrit \<30 %
  • Potassium \<3.0 mmol/L
  • Glucose \<50 mg/dl.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Physiologic estrogen replacement

    Mature girls with anorexia nervosa (AN) (bone age 15 or greater): Transdermal estradiol (100 mcg) with cyclic progesterone (days 1-10 of each month). Immature girls with AN (bone age less than 15 years): Ethinyl estradiol (3.75 mcg daily for the first 6 months, 7.5 mcg daily for the next 6 months, and 11.25 mcg daily for the final 6 months of the study

    Drug: Physiologic Estrogen/progesterone

  • Placebo comparator
    Placebo

    Placebo patches or pills

    Other: Placebo

Interventions

  • DrugPhysiologic Estrogen/progesterone

    Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month

    Also known as: Bone age >=15: Vivelle Dot patch with cyclic Provera

  • OtherPlacebo

    Placebo patches twice weekly; Placebo pills daily for the first 10 days of every month

06

What researchers measure

Primary outcomes

  1. Percent Change in Spine Bone Density Over the Study Duration (18 Months)

    Bone density at the spine (lumbar 1-4 vertebrae) was measured using dual energy x-ray absorptiometry (DXA) at baseline, 6 months, 12 months and 18 months. The primary outcome was the percent change in bone density at the spine from baseline to 18 months. Areal bone density is measured as g/cm2. The unit of measure for the percent change in bone density is 'percent' Percent change in bone density= \[\[Bone density at 18 months- Bone density at baseline)\*100/Bone density at baseline\]%

    Time frame: Baseline and 18 months

  2. Change in Spine Bone Mineral Density Z-scores Over the Study Duration (18 Months)

    Bone density at the spine (lumbar 1-4 vertebrae) was measured using dual energy x-ray absorptiometry (DXA) at baseline, 6 months, 12 months and 18 months. The other primary outcome was the change in spine bone density Z-score from baseline to 18 months. The bone density Z-score is a standard deviation score that compares one's bone density to the mean for age and gender, and the Z-score, therefore, does not have any units. It is simply referred to as a Z-score. Change in bone density Z-score= \[Bone density Z-score at 18 months- Bone density Z-score at baseline\]

    Time frame: Baseline and 18 months

Secondary outcomes

  1. Change in N-terminal Propeptide of Type 1 Procollagen (P1NP) Over the Study Duration (18 Months)

    P1NP is a surrogate marker of bone formation that is measured in serum. P1NP levels were measured at baseline, 6, 12 and 18 months. A secondary outcome was the change in P1NP levels from baseline to 18 months: \[P1NP at 18 months - P1NP at baseline). The unit is ng/ml

    Time frame: Baseline and 18 months

07

Results

Posted Oct 10, 2011

Participant flow

Period of recruitment: 2003-2009. Location: Massachusetts General Hospital (Boston) and Hospital for Sick Children (Toronto). We screened 150 girls with anorexia nervosa (AN) (110 at MGH and 40 at SickKids) and 88 normal-weight controls 12-18 years. Following the screen, 110 AN and 40 controls were enrolled for the prospective study.

Participant flow — Overall Study
MilestonePhysiologic Estrogen ReplacementPlacebo
Started5555
Completed3130
Not completed2425
Withdrew: Physician decision33
Withdrew: Withdrawal by subject1010
Withdrew: Lost to follow-up1112

Outcome measures

PrimaryPercent Change in Spine Bone Density Over the Study Duration (18 Months)

Bone density at the spine (lumbar 1-4 vertebrae) was measured using dual energy x-ray absorptiometry (DXA) at baseline, 6 months, 12 months and 18 months. The primary outcome was the percent change in bone density at the spine from baseline to 18 months. Areal bone density is measured as g/cm2. The unit of measure for the percent change in bone density is 'percent' Percent change in bone density= \[\[Bone density at 18 months- Bone density at baseline)\*100/Bone density at baseline\]%

Time frame:
Baseline and 18 months
Reported as:
Mean · Percent change
Percent Change in Spine Bone Density Over the Study Duration (18 Months)
Percent changePhysiologic Estrogen ReplacementPlacebo
Percent Change in Spine Bone Density Over the Study Duration (18 Months)2.6 ± 1.00.3 ± 0.1
Statistical analysis
  • Physiologic Estrogen Replacement vs Placebo · t-test, 2 sided · p = <0.05 (After controlling for baseline age and weight changes)We also used a mixed model analysis of variance (PROC MIXED), to analyze longitudinal data.
SecondaryChange in N-terminal Propeptide of Type 1 Procollagen (P1NP) Over the Study Duration (18 Months)

P1NP is a surrogate marker of bone formation that is measured in serum. P1NP levels were measured at baseline, 6, 12 and 18 months. A secondary outcome was the change in P1NP levels from baseline to 18 months: \[P1NP at 18 months - P1NP at baseline). The unit is ng/ml

Time frame:
Baseline and 18 months
Reported as:
Mean · ng/ml
Change in N-terminal Propeptide of Type 1 Procollagen (P1NP) Over the Study Duration (18 Months)
ng/mlPhysiologic Estrogen ReplacementPlacebo
Change in N-terminal Propeptide of Type 1 Procollagen (P1NP) Over the Study Duration (18 Months)-2.9 ± 22.5-10.9 ± 27.0
Statistical analysis
  • Physiologic Estrogen Replacement vs Placebo · t-test, 2 sided · p = >0.05
PrimaryChange in Spine Bone Mineral Density Z-scores Over the Study Duration (18 Months)

Bone density at the spine (lumbar 1-4 vertebrae) was measured using dual energy x-ray absorptiometry (DXA) at baseline, 6 months, 12 months and 18 months. The other primary outcome was the change in spine bone density Z-score from baseline to 18 months. The bone density Z-score is a standard deviation score that compares one's bone density to the mean for age and gender, and the Z-score, therefore, does not have any units. It is simply referred to as a Z-score. Change in bone density Z-score= \[Bone density Z-score at 18 months- Bone density Z-score at baseline\]

Time frame:
Baseline and 18 months
Reported as:
Mean · Z -scores
Change in Spine Bone Mineral Density Z-scores Over the Study Duration (18 Months)
Z -scoresPhysiologic Estrogen ReplacementPlacebo
Change in Spine Bone Mineral Density Z-scores Over the Study Duration (18 Months)-0.026 ± 0.078-0.236 ± 0.091
Statistical analysis
  • Physiologic Estrogen Replacement vs Placebo · t-test, 2 sided · p = <0.05 (The p value was adjusted for age and weight changes)

Adverse events

Collected over 18 months for each subject(AN E+ versus AN E-). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Physiologic Estrogen Replacement—12/55 (21.8%)18/55 (32.7%)
Placebo—16/55 (29.1%)20/55 (36.4%)
Most frequent serious events
Most frequent serious events
EventPhysiologic Estrogen ReplacementPlacebo
Hospitalizations for low weight and/or bradycardiaGeneral disorders12/5516/55
Increased vaginal bleedingReproductive system and breast disorders1/550/55
Erythema at patch application siteSkin and subcutaneous tissue disorders0/551/55
PregnancyReproductive system and breast disorders0/551/55
Suicidal ideationPsychiatric disorders1/551/55
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPhysiologic Estrogen ReplacementPlacebo
Erythema at patch application siteSkin and subcutaneous tissue disorders17/5519/55
BloatingGastrointestinal disorders18/5516/55
Nausea/vomitingGastrointestinal disorders14/558/55
HeadachesNervous system disorders10/5514/55
Breast tendernessReproductive system and breast disorders14/559/55
Increased vaginal dischargeReproductive system and breast disorders13/559/55
Increased uterine bleedingReproductive system and breast disorders13/559/55
DizzinessVascular disorders6/5510/55
Perceived loss of scalp hairSkin and subcutaneous tissue disorders8/555/55
Irritation from contact lensesEye disorders2/556/55

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Physiologic Estrogen ReplacementPlaceboTotal
<=18 years5555110
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)Physiologic Estrogen ReplacementPlaceboTotal
Mean16.6 ± 1.616.3 ± 1.616.5 ± 0.2
Sex: Female, Male
Sex: Female, Male(Participants)Physiologic Estrogen ReplacementPlaceboTotal
Female5555110
Male000
Region of Enrollment
Region of Enrollment(participants)Physiologic Estrogen ReplacementPlaceboTotal
United States5555110
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Publications

  • Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L, Weigel T, Mickley D, Schoenfeld DA, Herzog DB, Klibanski A. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res. 2011 Oct;26(10):2430-8. doi: 10.1002/jbmr.447. PubMed 21698665 ↗
  • Misra M, Katzman DK, Estella NM, Eddy KT, Weigel T, Goldstein MA, Miller KK, Klibanski A. Impact of physiologic estrogen replacement on anxiety symptoms, body shape perception, and eating attitudes in adolescent girls with anorexia nervosa: data from a randomized controlled trial. J Clin Psychiatry. 2013 Aug;74(8):e765-71. doi: 10.4088/JCP.13m08365. PubMed 24021517 ↗
  • Faje AT, Fazeli PK, Katzman DK, Miller KK, Breggia A, Rosen CJ, Mendes N, Klibanski A, Misra M. Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls. Bone. 2012 Sep;51(3):474-9. doi: 10.1016/j.bone.2012.06.006. Epub 2012 Jun 15. PubMed 22728230 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Feb 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2004
First posted
Jul 21, 2004
Start
Jul 2003
Primary completionActual
Feb 2011
CompletionActual
Jun 2011
Results first posted
Oct 10, 2011
Last update
Nov 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00088153
Responsible party
Madhusmita Misra (Chief, Pediatric Endocrinology, Massachusetts General Hospital) — Principal investigator
First posted
Jul 21, 2004
Start date
Jul 2003
Primary completion
Feb 2011
Completion
Jun 2011
Results posted
Oct 10, 2011
Last update
Nov 2, 2021

Study contacts

Madhusmita Misra, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion